AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Risk of Diabetes Following Sustained Statin Therapy Among Young Adults with Elevated Low-Density Lipoprotein Cholesterol

By An J, Zhou H, Juan R et al.

Objectives: Although statin therapy is recommended for young adults with elevated low-density lipoprotein cholesterol (LDL-C) and/or high estimated atherosclerotic cardiovascular (ASCVD) risk, concerns regarding statin-associated diabetes risk may be a barrier to its use in this population. We compared short- and long-term diabetes risk following sustained statin therapy versus no statin therapy among young adults with elevated LDL-C. Methods: We emulated a pragmatic trial of sustained statin therapy versus no therapy using observational data among adults aged 18-39 years from a US integrated health system. Eligible individuals had (1) LDL-C ≥190 mg/dL or (2) LDL-C 130-189 mg/dL and high estimated ASCVD risk (≥7.5% 10-year or ≥20% 30-year risk) between 2008-2017, and had no history of ASCVD, diabetes, or metformin use at baseline. Follow-up was through 2022. Sustained statin therapy was defined as initiation with continuous refills without gaps >90 days. Outcomes of interests were (1) incident type 2 diabetes, defined using inpatient/outpatient diabetes diagnoses, hemoglobin A1c (HbA1c) ≥6.5%, or diabetes medication use, and (2) untreated HbA1c. For incident diabetes, we estimated adjusted cumulative risk differences (RDs) and risk ratios (RRs) at 1 and 5 years using inverse probability weights for treatment, adherence, and censoring. We estimated adjusted mean HbA1c using weighted longitudinal models. Analyses were conducted in the overall population and stratified by baseline HbA1c (<5.7% and 5.7-<6.5%). Results: We included 6,751 statin initiators and 34,044 non-initiators (overall mean age 33 years, 27% female, mean LDL-C 186 mg/dL). For incident diabetes, adjusted RDs comparing sustained statin therapy versus no statin therapy were 2.2% (95% CI 1.6%, 3.0%) at 1 year and 3.0% (95% CI 0.7%, 4.9%) at 5 years; corresponding RRs were 2.13 (95% CI 1.80, 2.55) and 1.37 (95% CI 1.09, 1.62), respectively. Stratified analyses showed that the increased diabetes risk was observed among individuals with baseline HbA1c 5.7-<6.5% during early follow-up, but not in later years, and not among those with baseline HbA1c <5.7% ( Table ). Adjusted mean HbA1c levels were similar between groups during follow-up. Conclusions: Among young adults with elevated LDL-C, sustained statin therapy increased the risk of diabetes during early follow-up, particularly among those with baseline HbA1c in the prediabetes range. However, sustained statin therapy did not increase HbA1c levels, suggesting that the small absolute increase in diabetes risk may reflect earlier detection of diabetes in this population. These findings should be considered along with the ASCVD prevention benefits of statin therapy when making treatment decisions in young adults.

doi.org/10.1161/circ.154.suppl_1.6470Interventions

AgingResearch.News